Jordan J, Shannon J R, Biaggioni I, Norman R, Black B K, Robertson D
Clinical Research Center, Franz Volhard Clinic, Berlin, Germany.
Am J Med. 1998 Aug;105(2):116-24. doi: 10.1016/s0002-9343(98)00193-4.
Orthostatic hypotension is the most disabling symptom of autonomic failure. The choice of a pressor agent is largely empiric, and it would be of great value to define predictors of a response.
In 35 patients with severe orthostatic hypotension due to multiple system atrophy or pure autonomic failure, we determined the effect on seated systolic blood pressure (SBP) of placebo, phenylpropanolamine (12.5 mg and 25 mg), yohimbine (5.4 mg), indomethacin (50 mg), ibuprofen (600 mg), caffeine (250 mg), and methylphenidate (5 mg). In a subgroup of patients, we compared the pressor effect of midodrine (5 mg) with the effect of phenylpropanolamine (12.5 mg).
There were no significant differences in the pressor responses between patients with multiple system atrophy or pure autonomic failure. When compared with placebo, the pressor response was significant for phenylpropanolamine, yohimbine, and indomethacin. In a subgroup of patients, we confirmed that this pressor effect of phenylpropanolamine, yohimbine, and indomethacin corresponded to a significant increase in standing SBP. The pressor responses to ibuprofen, caffeine, and methylphenidate were not significantly different from placebo. Phenylpropanolamine and midodrine elicited similar pressor responses. There were no significant associations between drug response and autonomic function testing, postprandial hypotension, or plasma catecholamine levels.
We conclude that significant increases in systolic blood pressure can be obtained in patients with orthostatic hypotension due to primary autonomic failure with phenylpropanolamine in low doses or yohimbine or indomethacin in moderate doses. The response to a pressor agent cannot be predicted by autonomic function testing or plasma catecholamines. Therefore, empiric testing with a sequence of medications, based on the risk of side effects in the individual patient and the probability of a response, is a useful approach.
直立性低血压是自主神经功能衰竭最致残的症状。升压药的选择很大程度上是经验性的,确定反应的预测因素具有重要价值。
在35例因多系统萎缩或单纯自主神经功能衰竭导致严重直立性低血压的患者中,我们测定了安慰剂、苯丙醇胺(12.5毫克和25毫克)、育亨宾(5.4毫克)、吲哚美辛(50毫克)、布洛芬(600毫克)、咖啡因(250毫克)和哌甲酯(5毫克)对坐位收缩压(SBP)的影响。在一组患者中,我们比较了米多君(5毫克)与苯丙醇胺(12.5毫克)的升压效果。
多系统萎缩或单纯自主神经功能衰竭患者的升压反应无显著差异。与安慰剂相比,苯丙醇胺、育亨宾和吲哚美辛的升压反应显著。在一组患者中,我们证实苯丙醇胺、育亨宾和吲哚美辛的这种升压作用对应于站立位收缩压的显著升高。布洛芬、咖啡因和哌甲酯的升压反应与安慰剂无显著差异。苯丙醇胺和米多君引起相似的升压反应。药物反应与自主神经功能测试、餐后低血压或血浆儿茶酚胺水平之间无显著关联。
我们得出结论,低剂量苯丙醇胺、中等剂量育亨宾或吲哚美辛可使原发性自主神经功能衰竭所致直立性低血压患者的收缩压显著升高。升压药的反应不能通过自主神经功能测试或血浆儿茶酚胺来预测。因此,根据个体患者的副作用风险和反应概率,依次进行经验性药物试验是一种有用的方法。